Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 11, 2018, the Compensation Committee of the Board of Directors of Alder (the “Compensation Committee”) adopted the Alder BioPharmaceuticals, Inc. 2018 Inducement Award Plan (the “Inducement Plan”) to which Alder reserved 3,000,000 shares of its common stock for issuance under theInducement Plan. The only persons eligible to receive grants of Awards under theInducement Planare individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4). An “Award” is any right to receive Alder common stock to theInducement Plan, consisting of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or any other stock award. On June 11, 2018, the Compensation Committee also adopted forms of agreements for use with theInducement Plan.
The foregoing summary of the Inducement Plan is not intended to be complete and is qualified in its entirety by reference to the full text of the Inducement Plan, to be filed as an exhibit to the Company’s Quarterly Report onForm 10-Q forthe quarter ended June30, 2018. The forms of agreements for use with the Inducement Plan will also be filed as an exhibit to the Company’s Quarterly Report onForm 10-Q forthe quarter ended June30, 2018.
About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody.
